Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd., commonly referred to as AmoyDx, is a leading biotechnology company headquartered in China. Established in 2008, the company has made significant strides in the field of molecular diagnostics, focusing on oncology and infectious diseases. With a strong presence in Asia and expanding operations globally, AmoyDx is renowned for its innovative diagnostic solutions. The company offers a range of core products, including advanced PCR-based assays and next-generation sequencing (NGS) technologies, which are distinguished by their high sensitivity and specificity. AmoyDx has achieved notable recognition in the industry, positioning itself as a trusted partner for healthcare providers and researchers alike. With a commitment to enhancing patient outcomes, AmoyDx continues to drive advancements in precision medicine and diagnostics.
DitchCarbon Score
How does Amoy Diagnostics Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amoy Diagnostics Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amoy Diagnostics Co., Ltd.'s reported carbon emissions
Amoy Diagnostics Co., Ltd., headquartered in China, is committed to addressing climate change through various initiatives, although specific carbon emissions data is currently unavailable. The company has made a near-term commitment to reduce its carbon footprint, aligning with industry standards in the healthcare sector. As of October 2023, Amoy Diagnostics has not set a net-zero target but remains dedicated to improving its sustainability practices. The company is classified under the healthcare providers and services sector, indicating a focus on reducing emissions associated with its operations. While no specific reduction targets have been disclosed, the commitment to climate action is evident through its participation in the Science Based Targets initiative (SBTi), where it has registered its near-term target status as "Committed." This reflects a proactive approach to managing and mitigating carbon emissions in line with global climate goals. Overall, Amoy Diagnostics is taking steps towards enhancing its environmental responsibility, although further details on specific emissions metrics and reduction achievements are needed to fully assess its impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amoy Diagnostics Co., Ltd. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
